Form 4 for ABUS Arbutus Biopharma Corp

Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-01 · accession 0001447028-23-000011 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-02-03	2023-02-01	ABUS	McElhaugh Michael J.	Chief Business Off	A - Grant	$0.00	+83.7K	1.39M	+6%	$0
D	2023-02-03	2023-02-01	ABUS	McElhaugh Michael J.	Chief Business Off	A - Grant	$0.00	+334.7K	334.7K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2023-02-01	A	A	83,700	$0.00	1,391,157	D	—	—	(F1) Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
2	Derivative	Stock Option (Right to Buy)	2023-02-01	A	A	334,700	$0.00	334,700	D	$2.90 · — to 2033-02-01	334,700 Common Shares	(F2) This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.